Soluble cluster of differentiation 36 concentrations are not associated with cardiovascular risk factors in middle‑aged subjects

Alkhatatbeh,Mohammad  J.; Ayoub,Nehad M.; Mhaidat,Nizar M.; Saadeh,Nesreen A.; Lincz,Lisa F.

doi:10.3892/br.2016.622

Soluble cluster of differentiation 36 concentrations are not associated with cardiovascular risk factors in middle‑aged subjects

Authors:
- Mohammad J. Alkhatatbeh
- Nehad M. Ayoub
- Nizar M. Mhaidat
- Nesreen A. Saadeh
- Lisa F. Lincz
View Affiliations

Affiliations: Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan, Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan, Hunter Haematology Research Group, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia
Published online on: March 3, 2016 https://doi.org/10.3892/br.2016.622
Pages: 642-648

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cluster of differentiation 36 (CD36) is involved in the development of atherosclerosis by enhancing macrophage endocytosis of oxidized low‑density lipoproteins and foam cell formation. Soluble CD36 (sCD36) was found to be elevated in type 2 diabetic patients and possibly acted as a marker of insulin resistance and atherosclerosis. In young subjects, sCD36 was associated with cardiovascular risk factors including obesity and hypertriglyceridemia. The present study was conducted to further investigate the association between plasma sCD36 and cardiovascular risk factors among middle‑aged patients with metabolic syndrome (MetS) and healthy controls. sCD36 concentrations were determined by enzyme‑linked immunosorbent assays (ELISA) for 41 patients with MetS and 36 healthy controls. Data for other variables were obtained from patient medical records. sCD36 concentrations were relatively low compared to the majority of other studies and were not significantly different between the MetS group and controls (P=0.17). sCD36 was also not correlated with age, body mass index, glucose, lipid profile, serum electrolytes and blood counts. sCD36 was not significantly different between subjects with obesity, hyperglycemia, dyslipidemia, hypertension or cardiovascular disease, and those without these abnormalities (P>0.05). The inconsistency between results reported in the present study and other studies may be unique to the study population or be a result of the lack of a reliable standardized method for determining absolute sCD36 concentrations. However, further investigations are required to assess CD36 tissue expression in the study population and to assess the accuracy of various commercially available sCD36 ELISA kits. Thus, the availability of a standardized simple sCD36 ELISA that could be performed in any basic laboratory would be more favorable to the specialized flow cytometry methods that detect CD36+ microparticles if it was to be used as a biomarker.

View Figures

View References

1	Finegold JA, Asaria P and Francis DP: Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. Int J Cardiol. 168:934–945. 2013. View Article : Google Scholar : PubMed/NCBI
2	Tabei SM, Senemar S, Saffari B, Ahmadi Z and Haqparast S: Non-modifiable factors of coronary artery stenosis in late onset patients with coronary artery disease in Southern Iranian population. J Cardiovasc Thorac Res. 6:51–55. 2014.PubMed/NCBI
3	Cannon CP: Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 8:11–28. 2007. View Article : Google Scholar : PubMed/NCBI
4	Grundy SM: Metabolic syndrome: A multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 92:399–404. 2007. View Article : Google Scholar : PubMed/NCBI
5	Consultation WHO Definition, diagnosis and classification of diabetes mellitus and its complications. World Health Organization. Geneva, Switzerland: 31–33. 1999.
6	Balkau B and Charles MA: European Group for the Study of Insulin Resistance (EGIR): Comment on the provisional report from the WHO consultation. Diabet Med. 16:442–443. 1999. View Article : Google Scholar : PubMed/NCBI
7	Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285:2486–2497. 2001. View Article : Google Scholar : PubMed/NCBI
8	International Diabetes Federation: The IDF Consensus Worldwide Definition of the Metabolic Syndrome. International Diabetes Federation (Brussels, Belgium). 2006.
9	Ge Y and Wang TJ: Identifying novel biomarkers for cardiovascular disease risk prediction. J Intern Med. 272:430–439. 2012. View Article : Google Scholar : PubMed/NCBI
10	Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM and Topol EJ: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 290:898–904. 2003. View Article : Google Scholar : PubMed/NCBI
11	Montgomery JE and Brown JR: Metabolic biomarkers for predicting cardiovascular disease. Vasc Health Risk Manag. 9:37–45. 2013.PubMed/NCBI
12	van Holten TC, Waanders LF, de Groot PG, Vissers J, Hoefer IE, Pasterkamp G, Prins MW and Roest M: Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One. 8:e620802013. View Article : Google Scholar : PubMed/NCBI
13	Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK and Lee RT: Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 7:330–335. 1996. View Article : Google Scholar : PubMed/NCBI
14	Handberg A, Levin K, Højlund K and Beck-Nielsen H: Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: A novel marker of insulin resistance. Circulation. 114:1169–1176. 2006. View Article : Google Scholar : PubMed/NCBI
15	Park YM: CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Med. 46:e992014. View Article : Google Scholar : PubMed/NCBI
16	Bonen A, Campbell SE, Benton CR, Chabowski A, Coort SL, Han XX, Koonen DP, Glatz JF and Luiken JJ: Regulation of fatty acid transport by fatty acid translocase/CD36. Proc Nutr Soc. 63:245–249. 2004. View Article : Google Scholar : PubMed/NCBI
17	Alkhatatbeh MJ, Enjeti AK, Acharya S, Thorne RF and Lincz LF: The origin of circulating CD36 in type 2 diabetes. Nutr Diabetes. 3:e592013. View Article : Google Scholar : PubMed/NCBI
18	Glintborg D, Højlund K, Andersen M, Henriksen JE, Beck-Nielsen H and Handberg A: Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care. 31:328–334. 2008. View Article : Google Scholar : PubMed/NCBI
19	Handberg A, Skjelland M, Michelsen AE, Sagen EL, Krohg-Sørensen K, Russell D, Dahl A, Ueland T, Oie E, Aukrust P, et al: Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke. 39:3092–3095. 2008. View Article : Google Scholar : PubMed/NCBI
20	Khader Y, Batieha A, Jaddou H, El-Khateeb M and Ajlouni K: Metabolic Syndrome and Its Individual Components among Jordanian Children and Adolescents. Int J Pediatr Endocrinol. 2010:3161702010. View Article : Google Scholar : PubMed/NCBI
21	American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 33(Suppl 1): S62–S69. 2010.PubMed/NCBI
22	Ramos-Arellano LE, Muñoz-Valle JF, De la Cruz-Mosso U, Salgado-Bernabé AB, Castro-Alarcón N and Parra-Rojas I: Circulating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects. BMC Cardiovasc Disord. 14:542014. View Article : Google Scholar : PubMed/NCBI
23	Wu S, Yang D, Wei H, Wang B, Huang J, Li H, Shima M, Deng F and Guo X: Association of chemical constituents and pollution sources of ambient fine particulate air pollution and biomarkers of oxidative stress associated with atherosclerosis: A panel study among young adults in Beijing, China. Chemosphere. 135:347–353. 2015. View Article : Google Scholar : PubMed/NCBI
24	Krzystolik A, Dziedziejko V, Safranow K, Kurzawski G, Rać M, Sagasz-Tysiewicz D, Poncyljusz W, Jakubowska K, Chlubek D and Rać ME: Is plasma soluble CD36 associated with cardiovascular risk factors in early onset coronary artery disease patients? Scand J Clin Lab Invest. 75:398–406. 2015. View Article : Google Scholar : PubMed/NCBI
25	Himoto T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, Senda S, et al: Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease. Diabetol Metab Syndr. 5:512013. View Article : Google Scholar : PubMed/NCBI
26	García-Monzón C, Lo Iacono O, Crespo J, Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M, Domínguez-Díez A, de Rodríguez Cía J, Sáez A, Porrero JL, et al: Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. Eur J Clin Invest. 44:65–73. 2014. View Article : Google Scholar : PubMed/NCBI
27	Masuda Y, Tamura S, Matsuno K, Nagasawa A, Hayasaka K, Shimizu C and Moriyama T: Diverse CD36 expression among Japanese population: Defective CD36 mutations cause platelet and monocyte CD36 reductions in not only deficient but also normal phenotype subjects. Thromb Res. 135:951–957. 2015. View Article : Google Scholar : PubMed/NCBI
28	Ghosh A, Murugesan G, Chen K, Zhang L, Wang Q, Febbraio M, Anselmo RM, Marchant K, Barnard J and Silverstein RL: Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. Blood. 117:6355–6366. 2011. View Article : Google Scholar : PubMed/NCBI
29	Alexander Aguilera A, Hernández Díaz G, Lara Barcelata M, Angulo Guerrero O and Oliart Ros RM: Induction of Cd36 expression elicited by fish oil PUFA in spontaneously hypertensive rats. J Nutr Biochem. 17:760–765. 2006. View Article : Google Scholar : PubMed/NCBI
30	Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T and Asch AS: A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat Med. 7:840–846. 2001. View Article : Google Scholar : PubMed/NCBI
31	Tandon NN, Kralisz U and Jamieson GA: Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem. 264:7576–7583. 1989.PubMed/NCBI
32	Knøsgaard L, Thomsen SB, Støckel M, Vestergaard H and Handberg A: Circulating sCD36 is associated with unhealthy fat distribution and elevated circulating triglycerides in morbidly obese individuals. Nutr Diabetes. 4:e1142014. View Article : Google Scholar : PubMed/NCBI
33	Handberg A, Højlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, Piatti P and Beck-Nielsen H: RISC Investigators: Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med. 271:294–304. 2012. View Article : Google Scholar : PubMed/NCBI
34	Alkhatatbeh MJ, Mhaidat NM, Enjeti AK, Lincz LF and Thorne RF: The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. J Thromb Haemost. 9:844–851. 2011. View Article : Google Scholar : PubMed/NCBI
35	Chmielewski M, Bragfors-Helin AC, Stenvinkel P, Lindholm B and Anderstam B: Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients. Clin Chim Acta. 411:2079–1082. 2010. View Article : Google Scholar : PubMed/NCBI